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Principal components of ancestry analysis  
 
We performed genome-wide genotyping in subjects from the DCCT/EDIC [1, 2]. Genotype data 
were generated using the Illumina 1M beadchip assay (www.illumina.com, San Diego, CA) of 
which ~ 841K SNPs with a minor allele frequency >1% were subjected to subsequent statistical 
analysis. We limited the analysis to individuals who self-identified as white, and also excluded 
individuals who were determined to be admixed between Caucasian and other ethnic groups by 
population genetic approaches, using the software Eigenstrat [3], seeding with genotype data 
from the 3 major populations genotyped in HapMap phase II [4]. We selected SNPs for this 
latter analysis by first removing SNPs from regions known to be in strong linkage disequilibrium 
with each other (MHC, the polymorphic chromosome 8 inversion). Then we selected 
independent SNPs by requiring them to have r2<0.2 over a shifting window of 500kb. This 
resulted in ~ 98K SNPs being used for analysis. We then conducted a principal components 
analysis based on these 98K SNPs. The first three principal components which captured the 
largest proportion of the total variation between subjects were included in the regression 





SUPPLEMENTARY DATA  
 
©2013 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0256/-/DC1 
Supplementary Table 1.Effects of HP Type on Risk of Impaired GFR (Sustained eGFR<60mL/min/1.73m2) in 1303 
Caucasian DCCT/EDIC Participants with Principal Components of Ancestry Cox Proportional Hazard Model* 
 
  
DCCT Intensive Therapy (INT) 
 
DCCT Conventional Therapy (CON) 
DCCT 
Treatment 








































Risk Reduction by 
INT 
(%, 95 CI) 
            
1-1 76 1 1621 0.6 1 93 5 1953 2.6 1 76% (-97%, 106%) 
P=0.19 
            
2-1 323 9 7071 1.3 2.1  
(0.3, 16.2) 
295 15 6299 2.4 0.9 
 (0.3, 2.6) 
48% (-20%, 77%) 
P=0.12 
            
2-2 237 10 5235 1.9 3.1  
(0.4, 24.2) 
279 24 5793 4.1 1.7  
(0.6, 4.4) 
56% (8%, 79%) 
P=0.031 
 
Trend in risk of GFR 
across HP Type** 
 
Trend in risk of GFR 
across 0, 1, 2 Risk Allele 2: 
P=0.65 
 
Trend Test Z Value 
 
Trend P value 
Interaction 
between HP Type 







*Effect of HP type and DCCT treatment group on risk of impaired GFR defined as sustained eGFR<60 was assessed by a Cox proportional 
hazards model after adjustment for DCCT baseline estimated GFR, an interaction term of HP type and DCCT treatment group, and three 
principal components of ancestry. 
** Trend test is based on a Wald Chi-square test from a Cox proportional hazards model assessing the effect of number of HP 2 allele (0, 1, 
2) on risk of impaired GFR after adjustment for DCCT baseline estimated GFR, an interaction term of number of HP 2 allele and DCCT 
treatment group, and three principal components of ancestry. 
SUPPLEMENTARY DATA  
 
©2013 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0256/-/DC1 
Supplementary Table 2. Effects of HP Type on Rate of Change in estimated GFR in 1303 Caucasian DCCT/EDIC 







Rate of Change in eGFR in DCCT and EDIC  
(mL per minute per 1.73 m2 per year)  
DCCT Treatment 
Effect by HP Type * 
 
DCCT Intensive Therapy 
 
DCCT Conventional Therapy 
Rate of Decline 
Reduction by Intensive 





-1.43 (-1.63, -1.23) 
P<.0001^ 
 























Trend in GFR Slope Across  
Haptoglobin Types** 
 
Change in GFR Slope  
Per One Additional HP Allele 2: 
P=0.74 
Slope Difference  
Per One Additional HP Allele 2 
-0.12 (-0.22, -0.01) 
 
X2= 4.82, P=0.028 
Interaction between HP 
Type & DCCT Therapy 
in GFR Slope (df=2) 
P=0.38  
*Effect of HP type and DCCT treatment group on rate of change in estimated GFR in each treatment group was assessed by a 
General Linear Mixed Model by allowing for random intercept and random slope, after adjustment for DCCT baseline estimated GFR, 
DCCT treatment group, HP type, a three-way interaction term of DCCT treatment group, HP type, and time, and three principal 
components of ancestry. 
** Trend test is based on a variation of the Cochran-Armitage trend test.  
^ P values indicate whether the respective slope or rate of change in eGFR is significantly different from 0, i.e., a flat slope. 
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